In a murine model of multiple sclerosis, i.e. experimental autoimmune encephalomyelitis, anti-DNAM-1 treatment delayed the onset and reduced the severity of the disease [40]. This evidence concerns the gene CD226 and experimental autoimmune encephalomyelitis.